Cargando…

Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4

Epigenetic abnormalities play important roles in the pathogenesis of Hodgkin lymphoma (HL). Highly expressed class I histone acetyltransferase (HDAC) and hyper-methylation of the promoter region of tumor suppressor genes have been demonstrated in Hodgkin lymphoma. In this paper, we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Tao, Wang, Fujue, Hu, Lianjie, Cheng, Xiaomin, Zheng, Yuhuan, Liu, Ting, Jia, Yongqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652801/ https://www.ncbi.nlm.nih.gov/pubmed/29100410 http://dx.doi.org/10.18632/oncotarget.20659

Ejemplares similares

Correction: Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4
por: Jiang, Tao, et al.
Publicado: (2018)

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
por: Ridwansyah, Hastono, et al.
Publicado: (2023)

Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism
por: Li, Gangping, et al.
Publicado: (2021)

Chidamide in the treatment of peripheral T-cell lymphoma
por: Chan, Thomas S, et al.
Publicado: (2017)

PU.1 interacts with KLF7 to suppress differentiation and promote proliferation in chicken preadipocytes: Role of PU.1 and KLF7 in chicken preadipocytes
por: Tan, Ming, et al.
Publicado: (2023)

The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer
por: Zhang, Wanjun, et al.
Publicado: (2020)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report
por: Hu, Shaoxuan, et al.
Publicado: (2020)

Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial
por: Xia, Yi, et al.
Publicado: (2023)

Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
por: Zhao, Haijun, et al.
Publicado: (2022)

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
por: Cao, Liqin, et al.
Publicado: (2022)

Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis
por: Gao, Jie, et al.
Publicado: (2021)

Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report
por: Wang, Xing-Tong, et al.
Publicado: (2020)

Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report
por: Ding, Xiao-Sheng, et al.
Publicado: (2021)

Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer
por: Li, Jieqing
Publicado: (2023)

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine
por: Yao, Yushi, et al.
Publicado: (2013)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
por: Shi, Mingyue, et al.
Publicado: (2019)

Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
por: Kang, Junnan, et al.
Publicado: (2021)

Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report
por: Zhou, Zhencang, et al.
Publicado: (2022)

Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma
por: Wang, Jinni, et al.
Publicado: (2022)

Long‐term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine‐plus‐camrelizumab epi‐immunotherapy and treatment cessation
por: Wang, Chunmeng, et al.
Publicado: (2023)

The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study
por: Zhang, Wei, et al.
Publicado: (2021)

Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study
por: Wang, Lixin, et al.
Publicado: (2020)

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
por: Liu, Yang, et al.
Publicado: (2021)

Long-term follow up of Hodgkin lymphoma
por: Perez-Callejo, David, et al.
Publicado: (2018)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

P1201: A REAL-WORLD STUDY OF CHIDAMIDE FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA IN CHINA
por: Wang, Xin, et al.
Publicado: (2023)

Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up
por: Zhu, Fang, et al.
Publicado: (2020)

Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl-2 pathway
por: Zhang, Hongwei, et al.
Publicado: (2021)

Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia
por: Gu, Siyu, et al.
Publicado: (2023)

Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review
por: Jin, Jingxia, et al.
Publicado: (2018)

Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma
por: Tian, Chen, et al.
Publicado: (2020)

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide
por: Chen, Jinghong, et al.
Publicado: (2023)

MicroRNA-7 Regulates Migration and Chemoresistance in Non-Hodgkin Lymphoma Cells Through Regulation of KLF4 and YY1
por: Morales-Martinez, Mario, et al.
Publicado: (2020)

Pu /
por: Ramírez, Armando
Publicado: (2003)

Pu /
por: Ramírez,R. Armando
Publicado: (1977)

Single nucleotide polymorphisms of microRNA processing genes and outcome of non-Hodgkin’s lymphoma
por: Gao, Yuhuan, et al.
Publicado: (2015)

Combination of betulinic acid and chidamide synergistically inhibits Epstein-Barr virus replication through over-generation of reactive oxygen species
por: Yu, Haibing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lp4u59fst82qg6tk597untdend